Expression of Ccl2 and Ccl8 in Tet2 ^WT -CCl ₄ and Tet2 ^ΔMye -CCl ₄ mice and the effect of CCL2 and CCL8 inhibition on liver fibrosis progression. (A and B) Changes in (A) Ccl2 and (B) Ccl8 mRNA levels detected by RT-PCR in liver tissues of Tet2^WT-CCl₄ and Tet2^ΔMye-CCl₄ mice (Tet2^WT, n = 4; Tet2^ΔMye, n = 4; Tet2^WT-CCl₄, n = 5; Tet2^ΔMye-CCl₄, n = 5). (C–F) Detection of CCL2 and CCL8 level in Tet2^+/+and Tet2^−/− monocytes (C and D), granulocytes (E), and DCs (F) (n = 5 for each group). (G) Treatment schedule of Bindarit or PBS for Tet2^WT-CCl₄ and Tet2^ΔMye-CCl₄ mice. (H) Immune cell infiltration and the pathological structure of livers were evaluated by H&E staining for PBS and Bindarit in Tet2^WT-CCl₄ and Tet2^ΔMye-CCl₄ mice (n = 3). Green arrows indicate infiltrated immune cells in liver tissues. Scale bar, 100 μm. (I and J) mRNA levels of Col1a1 (I) and Acta2 (J) in livers of Tet2^WT-CCl₄ and Tet2^ΔMye-CCl₄ mice treated with PBS or Bindarit (n = 3 for each group). (K and L) Changes in serum ALT (K) and AST (L) after Bindarit treatment in Tet2^WT-CCl₄ and Tet2^ΔMye-CCl₄ mice (n = 4 for each group). (M) Representative flow cytometry graphs of MDMs in liver tissues of Tet2^WT-CCl₄ and Tet2^ΔMye-CCl₄ mice treated with PBS or Bindarit. Data are representative of at least two independent experiments with similar results (A–F and I–L). All data are shown as mean ± SD and were analyzed by two-tailed, paired Student’s t test (C–F) or two-way ANOVA with Sidak’s multiple comparison test (A, B, and I–L). ***P < 0.001; **P < 0.01; *P < 0.05; P > 0.05 not significant (ns).